Daiichi showed the mechanism can work in TGCT years ago, publishing phase 3 data in 2018 and winning FDA approval for Turalio ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has ...

Merck is pinning hopes on PAH drug Winrevair to boost its top line once Keytruda loses exclusivity. Merck’s stock is reasonably valued and buying this fundamentally strong company at the current ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

An acquisition by Merck was “hard to resist” given the company’s long history and expertise in drug development, experience ...

and a slightly underwhelming post launch revenue figure of $70m for pulmonary arterial hypertension drug Winrevair, which Merck has suggested could be a ~$6bn peak revenue drug. Winrevair has ...

Merck's most important product is Keytruda, a cancer drug that has won approval ... a therapy for pulmonary arterial hypertension with a new mechanism of action. According to some analysts ...

Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension. The agency recommended the ...

KIRKLAND, QC, Nov. 8, 2024 /CNW/ - Merck ... Canada's Drug Agency (CDA) has recommended WINREVAIR® (sotatercept) for reimbursement in combination with standard pulmonary arterial hypertension ...